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PrognosisBackground and purpose: The purpose of this study was to evaluate the 7th edition UICC/AJCC staging
system for nasopharyngeal carcinoma (NPC) patients who were treated with intensity modulated
radiation therapy (IMRT).
Materials and methods: The clinical data of 1241 NPC patients with initial magnetic resonance imaging
(MRI) scans were studied retrospectively. All MRIs were independently reevaluated and restaged
according to the 7th edition by two radiologists specializing in head and neck cancers. Analysis of
prognostic factors in local relapse-free survival (LRFS), distant metastasis-free survival (DMFS),
disease-speciﬁc survival (DSS), and overall survival (OS) were performed.
Results: The proportion of patients in Stage I, II, III, IVA and IVB were 4.8%, 26.2%, 45.4%, 18.4%, and 5.2%,
respectively. The differences of LRFS between T1 and T2, and between T2 and T3 were not signiﬁcant
(P = 0.055 and 0.605, respectively). Hazard ratios (HRs) for DSS and OS between T2 and T3 or between
T3 and T4 differed signiﬁcantly, but not between T1 and T2. The differences of DMFS between N0 and
N1, between N1 and N2 were signiﬁcant. However no signiﬁcant difference was found in DMFS between
N2 and N3a, or between N2 and N3b. For patients with T1–T3 disease, although skull base inﬁltration did
not impact local failure, it was an independent prognostic factor for both distant failure and cancer death.
Conclusion: When treated with IMRT, the difference in the LRFS, DSS, and OS between T1 and T2 patients
diminished, indicating that it is rational to merge T2 into T1. The prognostic value of the N classiﬁcation
of the current staging system had not changed much compared to the 6th edition.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Nasopharyngeal carcinoma (NPC) is the most common head and
neck malignancy in South China, and it is highly sensitive to radio-
therapy or chemotherapy [1]. Radiotherapy alone or combined
with chemotherapy is the primary treatment depending on the dis-
ease stage [2]. Therefore, the precise stage is crucial in selecting
and determining treatment strategies for NPC.The 7th AJCC staging system for NPC, which is a revision based
on the 5th and 6th editions, is currently universally accepted [3].
With the extensive use of intensity modulated radiation therapy
(IMRT), even in locally advanced NPC, the 5-year local control rate
has exceeded 90% [4,5]. Therefore, the short comings of the current
TNM staging system in predicting the prognosis have been found
and proposals for revisions in the next edition have been raised
in recent studies [6–8]. However, any change of the staging crite-
rion should be based on sufﬁcient evidences from multiple centers
and/or large sample studies which can be applied worldwide [9].
In the present study, the clinical data from 1241 pathologically
conﬁrmed NPC patients, who were staged by magnetic resonance
imaging (MRI) and treated with radical IMRT, were collected retro-
spectively and analyzed to assess the validity of the 7th edition
AJCC staging system.
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Patient characteristics
A total of 1241 newly diagnosed NPC patients without distant
organ metastasis, who were treated at Fujian Provincial Cancer
Hospital between June 1, 2005 and Dec 31, 2010, were collected.
The retrospective analysis was approved by Fujian Provincial
Cancer Hospital Institutional Review Board. Although consent
was not speciﬁcally obtained for this retrospective review, all
information had been anonymized and de-identiﬁed prior to its
analysis. The patients included 938 men and 303 women (male:
female ratio, 3.1:1), with a median age of 46 yrs (range,
11–84 yrs). The majority of the patients (94.7%; 1175/1241) had
World Health Organization (WHO) type III histopathology, 53
patients (4.3%) with WHO type II, and 13 patients (1%) with
WHO type I
MRI scan
All patients underwent MRI with a 1.5-Telsa system (Singa
EXCITE III HD, WI, American GE Company). The area from the
central temporal lobe to the entrance of thoracic was examined
with a head-and-neck combined coil. Seven scanning sequences
including axial T1 fast spin-echo (FSE), sagittal T1 FSE, axial proton
density fat-suppressed (PD fs), coronal T1 short-tall inversion
recovery (STIR), axial T1 enhanced FSE fs, coronal T1 enhanced
FSE fs, and diffusion weighted imaging (DWI) were obtained in
MRI general scans. Among the above scanning sequences, the
coronal orientation was parallel to C3 and axial orientation was
perpendiculars to C3.
Clinical staging
All MRI scans were revaluated separately by two radiologists
specializing in head-and-neck cancers. Any disagreement was
resolved by consensus. Cranial nerve involvement in T4 disease
was evaluated according to physical examination rather than the
radiology imaging [10]. Masticator space involvement is deﬁned
as extension tumor of beyond the anterior surface of the lateral
pterygoid muscle, or lateral extension beyond the posterolateral
wall of the maxillary antrum and the pterygomaxillary ﬁssure
[11]. The clinical records and MRI results of all patients were
collected into a database to be restaged accurately according to
the criteria of the 7th edition of AJCC staging system.
Treatment
All patients were initially treated with deﬁnitive IMRT. A
detailed description of the IMRT had been published previously
[12]. Of the 1181 patients with Stage II–IVB disease, 1,048
(88.7%) patients were given platinum-based chemotherapy. The
sequence of chemotherapy used was induction in 263 (22.3%), con-
current in 69 (5.8%), adjuvant in 15 (1.3%), concurrent–adjuvant in
23 (1.9%), induction–concurrent in 216 (18.3%), induction–
adjuvant in 301 (25.5%), and induction–concurrent–adjuvant in
161 (13.6%). Whenever possible, salvage treatments (including
intracavitary brachytherapy, surgery, and chemotherapy) were
provided for patients who developed relapse or persistent disease.
Following-up and statistical analysis
The median following-up time was 57 months (range, 2–102
months). The following endpoints (measured from the ﬁrst day
of diagnosis to the ﬁrst deﬁning event) were estimated: localrelapse-free survival (LRFS), regional relapse-free survival (RRFS),
disease-speciﬁc survival (DSS) and overall survival (OS). The
survival data were analyzed with SPSS software, version 18.0
(SPSS, Inc., Chicago, IL, USA). The host factors, histological types,
and treatment characteristics among different subgroups were
compared and analyzed using the chi-square test. Survival curves
were created with the Kaplan–Meier method and compared with
the log-rank test. The Cox proportional hazards model was used
to test the hazard ratios of DSS. A two-tailed P value < 0.05 was
considered statistically signiﬁcant.Results
Patient distribution
According to the 7th edition AJCC TNM stage system, the Stage I,
II, III, IVA and IVB disease was 4.8%, 26.2%, 45.4%, 18.4%, and 5.2%,
respectively. There were no signiﬁcant differences in the host
factors, histological categories, and chemotherapy among the
different T categories. However, signiﬁcantly more patients with
advanced T categories had received additional radiation boost
treatment to the nasopharynx than patients with early T categories
because of residual disease after IMRT (P = 0.014, Table 1).
Patterns of treatment failure and survival
At the last following up, 230 (18.5%) patients had succumbed to
their disease and 1011 (81.5%) remained alive. The 5-year OS, DSS,
DMFS, RRFS and LRFS were 81.1%, 82.6%, 82.6%, 95.4%, and 92.9%
respectively. Local recurrences, regional recurrences and distant
metastases developed in 81 (6.5%), 52 (4.2%), and 207 (16.7%)
patients, whereas 49 patients (3.9%) presented with both locore-
gional recurrences and distant metastases.
T category
The 5-year LRFS in T1, T2, T3 and T4 were 97.9%, 93.8%, 94.2%,
and 82.9%, respectively (Fig. 1). The difference between T1 and
T3, T2 and T4, T3 and T4 were found to be signiﬁcance (P < 0.05),
and was almost statistically signiﬁcant between T1 and T2
(P = 0.055), however, there was no signiﬁcant difference between
T2 and T3 (P = 0.605). DSS and OS comparisons among the T cate-
gories are shown in Table 2. A higher T category was associated
with poorer DSS and OS. Hazard ratios (HRs) for DSS and OS
between T2 and T3 and between T3 and T4 differed signiﬁcantly,
but not between T1 and T2 (P = 0.070 and 0.235). When the T
categories were considered as three groups (T1 + T2, T3, and T4),
HRs for both DSS and OS differed signiﬁcantly between adjacent
T categories (Table 2).
N category
The 5-year DMFS were 94.2%, 84.5%, 75.3%, 70.2%, and 61.7% for
N0, N1, N2, N3a, and N3b, respectively (Fig. 2A). The survival
differences between N0 and N1, N1 and N2, N2 and N3b were
signiﬁcant. Although there were no signiﬁcant survival difference
found between N2 and N3a (P = 0.498) or N3a and N3b
(P = 0.389), there was a signiﬁcance difference in survival between
N2 and combined N3a and N3b (P = 0.046, Fig. 2B).
As the N category increased, the DSS and OS became poorer. HR
for DSS and OS between the N0 and N1, N1 and N2 differed
signiﬁcantly, but not between N2 and N3a, or N3a and N3b. When
combining N3a and N3b, the differences in HRs for both DSS and
OS between N3 and N2 were not signiﬁcant (P = 0.107 and 0.212,
Table 2).
Table 1
Patient characteristic of different T categories.
Characteristic No. of patients (%)
T1 T2 T3 T4 Total P value
Gender 0.402
Male 226(75.1) 177(73.4) 343(74.9) 192(79.7) 938(75.6)
Female 75(24.9) 64(26.6) 115(25.1) 49(20.3) 303(24.4)
Age (yrs) 0.188
<50 193(64.1) 148(61.4) 299(65.3) 138(57.3) 778(62.7)
>50 108(35.9) 93(38.6) 159(34.7) 103(42.7) 463(37.3)
Histology 0.978
WHO grade I 1(0.3) 6(2.5) 4(0.9) 2(0.8) 13(1.0)
WHO grade II 14(4.7) 14(5.8) 12(2.6) 13(5.4) 53(4.3)
WHO grade III 286(95.0) 221(91.7) 442(96.5) 226(93.8) 1175(94.7)
Chemotherapy in stage III–IV patients 0.725
No 5(6.5) 5(6.2) 35(7.6) 13(5.4) 58(6.8)
Yes 72(93.5) 75(93.8) 423(92.4) 228(94.6) 798(93.2)
Boost treatment 0.014
No 283(94.0) 220(91.3) 407(88.9) 214(88.8) 1124(90.6)
Yes 18(6.0) 21(8.7) 51(11.1) 27(11.2) 117(9.4)
N-stage 0.178
N0 60(19.9) 28(11.6) 63(13.8) 33(13.7) 184(14.8)
N1 164(54.5) 133(55.2) 243(53.0) 147(61.0) 687(55.4)
N2 67(22.3) 61(25.3) 129(28.2) 48(19.9) 305(24.6)
N3 10(3.3) 19(7.9) 23(5.0) 13(5.4) 65(5.2)
Fig. 1. Local relapse-free survival for different T classiﬁcations.
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The 5-year DSS was 97.2% for stage I, 90.6% for stage II, 82.9% for
stage III, 69.5% for stage IVA, and 68.9% for stage IVB (Fig. 3A). The
DSS curves showed fairly good separation among adjacent staging
groups. However, the difference between stage IVA and IVB does
not reach statistical signiﬁcance (P = 0.505). Although the OS
curves showed no statistically signiﬁcant difference between
stages I and II, and between stages IVA and IVB (P = 0.075 and
0.729 respectively), it still shows a relatively well segregated
distribution pattern for all stages (Fig. 3B).
Multivariate Cox regression analysis
Due to the closed LRFS in T1–3 patients, multivariate Cox
regression analysis was performed to evaluate various prognostic
factors deﬁned by T-categories. The following covariables were
included in the Cox proportion hazards model: age (<50 yrs
vs.>50 yrs), gender (male vs. female), chemotherapy (yes vs. no),
histology, N category, nasal fossa extension, oropharynx
inﬁltration, parapharyngeal extension, skull base inﬁltration, andparanasal sinuses involvement. No independent prognostic factor
was found for local failure. Skull base inﬁltration were statistically
signiﬁcant for distant failure, cancer death and death due to any
cause, whereas T1–T2 related factors such as nasal fossa extension,
oropharynx inﬁltration, and parapharyngeal involvement failed to
show signiﬁcant positive trends for all endpoints (Table 3).Discussion
The AJCC TNM classiﬁcation of NPC is a universally accepted
system to describe the anatomic extent of malignant tumors. To
reﬂect the understanding of the extent of the disease and its role
in prognosis, the TNM classiﬁcation has undergone signiﬁcant evi-
dence-based revisions [3]. The 7th staging system was revised
mainly based on the data from the two-dimensional conventional
radiotherapy era [10]. Currently, the IMRT has been conﬁrmed to
improve local control and reduce radiation-induced toxicities by
providing better tumor target coverage and is signiﬁcantly better
at sparing sensitive normal structures [12]. Despite of the contro-
versy as to whether early or advanced T Stage can beneﬁt from
IMRT, it is widely accepted as the standard treatment for NPC
[13,14]. Although there are still a certain percentage of patients
given conventional radiotherapy instead of IMRT due to limited
resources, the vast majority of NPC patients in the world will
receive IMRT. Therefore, to revise the TNM staging system and
make it applicable to patients treated with IMRT is inevitably the
future direction for further reﬁnement of NPC staging [6,7,15].
Lee [6] analyzed the data of 985 NPC patients treated with 3D-
conformal radiotherapy or IMRT and found that the difference in
the LRFS between T2 and T3 was signiﬁcant (P = 0.043), but not
between T1 and T2 (P = 0.99). The study considered that with mod-
ern treatment, the staging system could be further improved and
simpliﬁed by down-staging the current stage T2 patients to T1.
In addition, Chen et al. [7] previously reported a study of 512
NPC patients treated with IMRT, and found that the LRFS between
T1 and T2 patients were signiﬁcantly different, but not between
stage T2 and T3 patients. These reports indicated that the differ-
ences of local control among T1–3 patients will be diminished
when treated with 3DCRT or IMRT. However, how to simplify the
Table 2
Disease-speciﬁc survival and overall survival in nasopharyngeal carcinoma patients according to the 7th edition of TNM staging system.
Category Comparison Cancer death Death
5-yr DSS (%) HR (95% CI) P value 5-yr OS (%) HR (95% CI) P value
T category T1 92.2 90
T2 T2 vs. T1 86.6 1.658(0.960–2.865) 0.070a 85.7 1.357(0.82–2.249) 0.235a
T3 T3 vs. T2 81.2 1.544(1.029–2.316) 0.036a 80.0 1.566(1.057–2.322) 0.025a
T4 T4 vs. T3 69.1 1.708(1.239–2.355) 0.001a 67.6 1.663(1.219–2.268) 0.001a
T1 + T2 T3 vs. T1 + T2 89.7 1.892(1.344–2.665) <0.001a 88.1 1.792(1.295–2.48) <0.001a
N category N0 92 90.9
N1 N1 vs. N0 84.5 1.891(1.149–3.113) 0.012b 83.2 1.944(1.177–3.211) 0.009b
N2 N2 vs. N1 75.4 1.689(1.242–2.298) 0.001b 73.2 1.710(1.277–2.289) <0.001b
N3a N3a vs. N2 69.8 1.147(0.565–2.331) 0.704b 69.8 1.020(0.504–2.064) 0.957b
N3b N3b vs. N3a 67.6 1.611(0.649–4.001) 0.304b 67.6 1.611(0.649–4.001) 0.304b
N3 N3 vs. N2 68.9 1.493(0.917–2.432) 0.107b 68.9 1.359(0.839–2. 201) 0.212b
DSS = disease-speciﬁc survival; OS = overall survival; HR = hazard ratio; CI = conﬁdence interval.
a P value was calculated using Cox proportional hazards model after adjusting for age, gender, histology, chemotherapy and N category.
b P value was calculated using Cox proportional hazards model after adjusting for age, gender, histology, chemotherapy and T category.
Fig. 2. Distant metastasis-free survival for different N classiﬁcations: (A) N3 was divided into N3a and N3b, (B) N3 was the combination of N3a and N3b.
Fig. 3. Disease-speciﬁc survival (A) and overall survival (OS) for different overall stages.
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able is still controversial [6,7]. As indicated in this study, stage T4
patients had much worse survival compared to patients in other T
categories (T1–3), whereas, the LRFS between stage T1 and T2
patients and between stage T2 and T3 patients was not signiﬁ-
cantly different. Meanwhile, although the difference in DSS and
OS between stage T2 and T3 patients and between T3 and T4patients was signiﬁcant, it was not signiﬁcant between stage T1
and T2 patients (Table 1).
Further multivariate analysis were performed in stage T1–T3
patients, which revealed that the skull base inﬁltration was a sta-
tistically signiﬁcant factor for both distant failure and cancer death.
This indicated, that although the LRFS between stage T1 and T2 and
between stage T2 and T3 patients was not signiﬁcantly different,
Table 3
Independent prognostic factors by multivariate analyses for patient with T1–T3.
Endpoint Factor P value HR (95% CI)
Distant failure Skull base inﬁltration 0.018 1.559(1.081–2.250)
Gender 0.048 0.607(0.371–0.995)
Age 0.002 1.785(1.236–2.578)
N category <0.001 1.811(1.442–2.275)
Cancer death Skull base inﬁltration 0.007 1.681(1.154–2.448)
Age <0.001 2.661(1.830–3.871)
N category <0.001 1.897(1.504–2.394)
Death Skull base inﬁltration 0.008 1.613(1.131–2.3)
Age <0.001 3.009(2.105–4.3)
N category <0.001 1.807(1.448–2.266)
HR = hazard ratio, CI = conﬁdence interval.
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T2 disease. Merging the current T2 and T1 stages seems to be more
rational than merging stages T2 and T3. In the current study, when
the T categories were considered as three groups (T1 + T2, T3, and
T4), HRs of DSS and OS differed signiﬁcantly between adjacent T
categories (Table 2).
Although the AJCC staging system of NPC had been modiﬁed
constantly, there has been more updating and improvements of T
staging than of N staging [3]. There was no obvious change in N
staging after the fourth edition except the clear deﬁnition and clas-
siﬁcation of pharyngeal lymph node involvement [10]. Compared
to the previous conventional radiotherapy, the prognosis predic-
tion of N staging has not changed, even in the IMRT era [7,16,17].
The present study demonstrated the N staging is practical and it
can predict the prognosis in N1, N2 and N3 patients.
Due to the presence of rare NPC patients who are staged N3,
there had been several studies trying to challenge the existing
N3 staging criteria [17–19]. However, for the lack of a uniﬁed end-
point and of a sufﬁcient sample size to study, particularly for the
deﬁciency of uniﬁed objective criterion diagnosis of the N3 sub-
groups, a feasible revision opinion of N staging have not been
raised until now [10]. Two studies have reported that the predic-
tive value of the N classiﬁcation in the Chinese 2008 staging
system was superior to the 7th AJCC [15,20]. In the Chinese 2008
staging system, measurement of the lymph nodes was based on
MRI images rather than clinical palpation, which may differ among
clinicians. In addition, the site, size, laterality and extranodal
neoplastic spread to lymph nodes were all enrolled in the criteria
of N staging categories [21]. Although it may be objective to eval-
uate the site, size and laterality of lymph node involvement on
MRI, the measurement of the extranodal neoplastic spread is an
inevitable ambiguity. Therefore, revising a more sensible and reli-
able N classiﬁcation for the current AJCC staging system remains a
great challenge.
Concurrent chemoradiotherapy has been repeatedly proven to
improve survival [22,23]. However, only 39.7% (469/1181) of the
stage II–IVB patients received concurrent chemotherapy in the
study. Future prospective studies of IMRT combined with concur-
rent chemotherapy may be needed to evaluate its inﬂuence on
the staging system.
The current AJCC TNM staging system for NPC is based on the
anatomical extent of the tumor [24]. Tumor volume has been pro-
posed as an independent prognostic factor besides T classiﬁcation
in patients with NPC [25–27]. Our previous study also demon-
strated that the primary tumor volume had a signiﬁcant impacted
on the prognosis of NPC patients treated with IMRT. The 5-year OS
was signiﬁcantly reduced for patients with a large tumor volume
(>50 ml), which is almost equal to that of stage T4 patients [28].
To take tumor volume into consideration as an additional stage
indicator in the future revision of NPC staging, more studies shouldbe done to identify a uniform cut-off point of tumor volume. On the
other hand, new biomarkers such as miRNA or EBV DNA have been
recently reported as having prognostic value. To bring these new
molecular factors into the clinical staging system presents a most
challenging task [29,30].
In conclusion, regardless of the limitation of this being a single
center and retrospective study, our study indicated that the 7th
edition AJCC staging system still showed superior prognostic value
in NPC patients treated with IMRT. Because patients with T2
disease had similar LRFS to stage T1 patients, the proposal of down
stage T2 to T1 seemed to be reasonable. However, how to rationally
deal with the stage N3a needs more research.
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